FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2285-2287 November 24, 2005 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Demedts, M. PubMed Citation

Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterized by fibrosis and remodeling of the lung parenchyma. The median survival of patients with the disease is about three years after diagnosis or five years after the onset of symptoms. The pathological findings are those of usual interstitial pneumonia.¹ In many instances, the diagnosis can be made when typical clinical and radiologic features are present.^2,3,4,5 The classic radiologic features are a patchy pattern of peripheral "honeycombing" that is more prominent in the bases of the lungs, traction bronchiectasis, and the absence of prominent ground-glass opacity. When these findings are not present, . . . [Full Text of this Article]

Source Information

From the Department of Medicine, University of Iowa and Veterans Affairs Medical Center, Iowa City.

This article has been cited by other articles:

• Wolters, P. J. (2009). Could N-acetylcysteine slow progression of idiopathic pulmonary fibrosis by inhibiting EMT?. Am. J. Physiol. Lung Cell. Mol. Physiol. 297: L803-L804 [Full Text]  
• Lynch, J. P. III (2009). Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonia/Fibrosis, and Sarcoidosis. ACCP Pulmonary Med Brd Rev 25: 635-686 [Full Text]  
• Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., Fatenejad, S. (2008). Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial. Am. J. Respir. Crit. Care Med. 178: 948-955 [Abstract] [Full Text]  
• Vuorinen, K., Ohlmeier, S., Lepparanta, O., Salmenkivi, K., Myllarniemi, M., Kinnula, V. L. (2008). Peroxiredoxin II Expression and Its Association With Oxidative Stress and Cell Proliferation in Human Idiopathic Pulmonary Fibrosis. J. Histochem. Cytochem. 56: 951-959 [Abstract] [Full Text]  
• Wells, A U, Hirani, N, on behalf of the BTS Interstitial Lung Disease Gui, (2008). Interstitial lung disease guideline. Thorax 63: v1-v58 [Full Text]  
• Noth, I., Martinez, F. J. (2007). Recent Advances in Idiopathic Pulmonary Fibrosis. Chest 132: 637-650 [Abstract] [Full Text]  
• Wells, A. U., Hogaboam, C. M. (2007). Update in Diffuse Parenchymal Lung Disease 2006. Am. J. Respir. Crit. Care Med. 175: 655-660 [Full Text]  
• Raghu, G. (2006). Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches.. Eur Respir J 28: 463-465 [Full Text]  
• Martinez, F. J., Keane, M. P. (2006). Update in diffuse parenchymal lung diseases 2005.. Am. J. Respir. Crit. Care Med. 173: 1066-1071 [Full Text]  
• Wells, A. U. (2006). Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled.. Eur Respir J 27: 664-666 [Full Text]  
• Hull, J. H.K., Toma, T. P., Bhowmik, A., Rajakulasingam, R., Demedts, M., Buhl, R., Costabel, U., the IFIGENIA Study Group, (2006). Acetylcysteine in Pulmonary Fibrosis. NEJM 354: 1089-1091 [Full Text]  
• Martinez, F. J. (2006). Idiopathic Interstitial Pneumonias: Usual Interstitial Pneumonia versus Nonspecific Interstitial Pneumonia.. Proc Am Thorac Soc 3: 81-95 [Abstract] [Full Text]  
• (2005). Acetylcysteine for Idiopathic Pulmonary Fibrosis. JWatch General 2005: 3-3 [Full Text]